JPGN reportsOct 13, 2026

Tirzepatide treatment in teenagers with fatty liver disease linked to metabolism problems: A case series

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 14, 2026

Abstract

Tirzepatide may achieve a 20.2% weight reduction in adolescents with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

Tirzepatide targets both gastric inhibitory peptide and GLP-1 receptors.
It has shown superior weight loss compared to Semaglutide, which achieved a 13.7% reduction.
Adult studies suggest Tirzepatide is effective in resolving metabolic dysfunction-associated steatohepatitis (MASH).
Pediatric data indicate that Tirzepatide may be safe for younger populations.
No existing studies specifically evaluate Tirzepatide's effects on MASLD in pediatric patients.

Simplified

Pediatric obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence has risen markedly over the past decade. Due to transition delays and workforce shortages, pediatric specialists often manage patients into young adulthood, and thus familiarity with adult pharmacotherapies for MASLD is essential. Currently, Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for adults with metabolic dysfunction-associated steatohepatitis (MASH) and F2-F3 fibrosis; however, dual and triple agonists are being evaluated. Tirzepatide, a dual agonist that targets gastric inhibitory peptide (GIP) and the GLP-1 receptor, has demonstrated superior weight reduction to Semaglutide (-20.2% vs. -13.7%) with a more favorable gastrointestinal adverse effect profile. Adult literature has demonstrated its effectiveness in MASH resolution, and pediatric data suggest it is safe in younger populations. Currently, there are no pediatric/adolescent studies exploring the use of Tirzepatide in MASLD. We present our experience using Tirzepatide in two adolescent patients with obesity and MASLD.

Full Text

Full text is available at the source.

View Full Text ↗

Tirzepatide treatment in teenagers with fatty liver disease linked to metabolism problems: A case series

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief